|

GPC3-Targeted PET/CT in Hepatocellular Carcinoma

RECRUITINGN/ASponsored by The First Affiliated Hospital of Xiamen University
Actively Recruiting
PhaseN/A
SponsorThe First Affiliated Hospital of Xiamen University
Started2026-05-01
Est. completion2028-05-31
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07677774

Summary

The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with 18F-FDG PET/CT.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Adult patients (aged 18 years or older);
* Patients with suspected, newly diagnosed, or previously treated hepatocellular carcinoma(supporting evidence may include imaging findings and pathology report);
* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;

Exclusion Criteria:

* The inability or unwillingness of the research participant or legal representative to provide written informed consent.
* Inability to complete PET/CT imaging.

Conditions6

CancerGPC3-targeted PET/CTGlypican-3Hepatocellular Carcinoma (HCC)Liver CancerLiver Disease

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.